Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 4/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556818 | 0.91 | MMP8 (0.56) | MMP8MMP2MMP9 | |
| SCHEMBL5558701 | 0.89 | MAPT (0.46) | MMP8MMP2MMP9MAPTCTSK | |
| SCHEMBL5556462 | 0.86 | MMP2 (0.63) | MMP8MMP2MMP9 | |
| SCHEMBL5556645 | 0.85 | KMT2A (0.55) | MMP8MMP2MMP9MAPTTP53 | |
| SCHEMBL5558599 | 0.80 | MMP9 (0.57) | MMP8MMP2MMP9NPC1RAB9A | |
| SCHEMBL5552855 | 0.79 | ERAP2 (0.59) | MMP8MMP2MMP9TP53 | |
| SCHEMBL5552466 | 0.79 | ATM (0.49) | MMP8MMP2MMP9NPC1RAB9A | |
| SCHEMBL4841051 | 0.76 | CA2 (0.47) | MMP8MMP2MMP9NPC1RAB9A | |
| SCHEMBL5556442 | 0.76 | TSHR (0.48) | MMP8MMP9KCNH2 | |
| SCHEMBL5552342 | 0.75 | MMP2 (0.60) | MMP8MMP2MMP9MAPTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MMP8 24/4885MMP2 85/4885MMP9 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.